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Abstract: Cocoa has beneficial health effects partly due to its high flavanol content. This study was
aimed at assessing the absorption and metabolism of polyphenols in two soluble cocoa products: a
conventional (CC) and a flavanol-rich product (CC-PP). A crossover, randomized, blind study was
performed in 13 healthy men and women. On two different days, after an overnight fast, volunteers
consumed one serving of CC (15 g) or CC-PP (25 g) in 200 mL of semi-skimmed milk containing
19.80 mg and 68.25 mg of flavanols, respectively. Blood and urine samples were taken, before and after
CC and CC-PP consumption, and analyzed by high-performance liquid chromatography coupled
to electrospray ionisation and quadrupole time-of-flight mass spectrometry (HPLC-ESI-QToF-MS).
Up to 10 and 30 metabolites were identified in plasma and urine, respectively. Phase II derivatives
of epicatechin were identified with kinetics compatible with small intestine absorption, although
the most abundant groups of metabolites were phase II derivatives of phenyl-γ-valerolactone and
phenylvaleric acid, formed at colonic level. 5-(4′-Hydroxyphenyl)-γ-valerolactone-sulfate could be a
sensitive biomarker of cocoa flavanol intake. CC and CC-PP flavanols showed a dose-dependent
absorption with a recovery of 35%. In conclusion, cocoa flavanols are moderately bioavailable and
extensively metabolized, mainly by the colonic microbiota.
Keywords: flavanols; soluble cocoa products; bioavailability; human; plasma nutrikinetics; liquid
chromatography coupled to electrospray ionisation and quadrupole time-of-flight mass spectrometry
(LC-ESI-QToF-MS); colonic bacteria
1. Introduction
Cocoa remains a popular foodstuff worldwide. Soluble cocoa products have been popular in
Spain, among other countries, being commonly consumed twice a day, at breakfast and as part of an
afternoon break known as “merienda”. The potential health-promoting effects of cocoa products have
gained extensive attention in the last few years. Most of these effects are attributed to the polyphenolic
fraction of cocoa, mainly flavanols epicatechin and catechin, and low molecular weight procyanidins
such as procyanidins B1 and B2 [1,2]. In fact, cocoa has been defined as a functional food due to its high
flavanol content [1]. Moreover, soluble cocoa products are also a source of methylxanthines (mainly
theobromine), magnesium and dietary fiber; all are biologically active substances that may also affect
human health positively [2].
The biological activity of phenolic compounds depends on their bioavailability and metabolic fate,
as well as on their digestive accessibility, which is determined by the release from the food matrix and
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efficiency in trans-epithelial passage. Recently Mena et al. [3] reviewed the rate and extent of absorption
of cocoa polyphenols in humans, as well as the metabolic pathways involved. These polyphenols
are partially absorbed in the upper gastrointestinal tract, being conjugated by phase II enzymes into
methoxy, sulfated and/or glucuronidated metabolites, with maximum plasma concentrations around
2 h after cocoa intake in the nM range [4]. Controversy exists regarding whether procyanidins can be
broken down in the stomach yielding monomers that may be absorbed or, conversely, whether intact
procyanidins can be absorbed from the gastrointestinal tract. In this sense, Ottaviani et al. [5] observed
that dietary procyanidins do not contribute to the systemic pool of flavanols in humans when test
drinks that contained only flavanols, flavanols and procyanidins, or only procyanidins were consumed
by humans.
Polyphenols not absorbed in the small intestine reach the colon where they are metabolized by
the intestinal microbiota mainly to phenyl-γ-valerolactone and phenylvaleric acid metabolites [3].
These ring fission products, as well as phenylvaleric acid conjugates, were excreted primarily
5–10 h after ingestion of green tea [6,7]. In a recent report on the absorption, distribution,
metabolism, and excretion in humans of radiolabeled and stereochemically pure [2-14C](-)-epicatechin
([14C]epicatechin) [8], 20 different metabolites were identified and quantified: phase II derivatives of
epicatechin, hydroxyphenyl-γ-valerolactones and phenylvaleric acids. Moreover, it was confirmed
that the gut microbiome is a key driver of epicatechin metabolism.
Nowadays, innovation in the elaboration of cocoa products includes using new delivery forms
in an attempt to increase polyphenols’ bioavailability, like microencapsulation of cocoa phenols in
cocoa-nut creams [9]. New soluble cocoa products enriched with bioactive components such as dietary
fiber, methylxanthines or polyphenols are also being introduced into the food market. This is the case
of two novel soluble cocoa products, produced and commercialized by the same manufacturer as the
products used in the present study. One is rich in dietary fiber and the other rich in cocoa, containing
1.16 and 3.02 mg/g of flavanols, respectively [10]—amounts similar to the flavanol content of the
soluble cocoas used in the present study (see below). When consumed in realistic doses by healthy
and subjects at cardiovascular risk (hypercholesterolemic), results showed that both soluble cocoa
products had a positive effect on serum lipid profile, increasing HDL-cholesterol without inducing
anthropometric changes. These effects could be associated in part to the flavanol content in the two
commercial cocoa products, although in that study the circulating levels of phenolic metabolites was
not quantified. However, other studies have shown a correlation between the effect of dark chocolate
(50 g, providing 7.5 gallic acid equivalents (GAE) of polyphenols) improving platelet function and
the increased plasma concentrations of structurally-related (epi)catechin metabolites (SREM). These
data confirm that the potential health benefits of cocoa consumption may be mediated by flavan-3-ol
circulating metabolites [11], in spite of the limited bioavailability of cocoa polyphenols.
Indeed, many studies have focused on determining the bioavailability and metabolism of cocoa
phenolic compounds, although most bioavailability studies have been carried out with unrealistic
doses (for some reviews see [3,12–14]). Therefore, the aim of the present work was to evaluate the
bioavailability of flavanols in healthy humans after consuming a realistic amount of two soluble cocoa
products: a conventional soluble cocoa (CC) and a flavanol-rich soluble cocoa (CC-PP). In addition, an
important effort has been made to identify microbiota-derived metabolites, showing the importance of
gut bacteria on polyphenol absorption and metabolism.
2. Materials and Methods
2.1. Chemical Reagents and Materials
The commercialized soluble cocoa products used in the study were provided by Idilia Foods
(previous company name: Nutrexpa S.L.), one being a conventional soluble cocoa product, labeled
as CC, and the other a flavanol-rich soluble cocoa product, labeled as CC-PP. All solvents and
reagents were of analytical grade unless otherwise stated. Ascorbic acid, epicatechin, catechin,
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procyanidin B1, 3-(3,4-dihydroxyphenyl)propionic acid, 3-(4-hydroxyphenyl)propionic acid, 3-(4-
hydroxy-3-methoxyphenyl)propionic acid, 3,4-dihydroxyphenylacetic acid, 4-hydroxyphenylacetic
acid, 4-hydroxy-3-methoxyphenylacetic acid, protocatechuic acid, 4-hydroxybenzoic acid and ferulic
acid were from Sigma-Aldrich (Madrid, Spain). Procyanidin B2 and epicatechin-3-gallate were acquired
from Extransynthese Genay Cedex (France). Methanol, formic acid, and acetonitrile (high-performance
liquid chromatography (HPLC) grade) were acquired from Panreac (Madrid, Spain).
2.2. Quantification of Total Polyphenols of the Soluble Cocoa Products. Characterization and Quantification by
high-performance liquid chromatography-mass spectrometry (HPLC-MS) and high-performance liquid
chromatography-diode array (HPLC-DAD).
Total polyphenols were measured spectrophotometrically using the Folin–Ciocalteau reagent and
gallic acid as standard. Results were expressed as µg equiv gallic acid/g product.
As described by Bravo et al. [15], cocoa extracts were obtained by washing 1 g of defatted cocoa
with 40 mL of 50% aqueous methanol (HPLC grade) containing 0.8% of 2 mol/L hydrochloric acid for 1 h
at room temperature with constant shaking. Afterwards, samples were centrifuged (10 min, 3000× g)
and supernatants were collected. The residues obtained were successively extracted with 40 mL of 70%
acetone (v/v) in water (1 h, constant shaking). The samples were then centrifuged (10 min, 3000× g) and
supernatants were collected. Finally, supernatants obtained after each extraction step were combined
and made up to 100 mL. Polyphenolic composition was analyzed using an Agilent 1200 series liquid
chromatographic system equipped with an autosampler, quaternary pump, diode array detector
(DAD) and simple quadrupole (sQ) mass spectrometer (Agilent Technologies, Waldbronn, Germany).
Samples (20 µL) were injected into a Superspher RP18 column (4.6 mm × 250 mm i.d., 4 µm; Agilent
Technologies) preceded by an ODS RP18 guard column kept in a thermostatic oven at 37 ◦C.
Elution was performed at a flow rate of 0.6 mL/min using a binary system consisting of 1% formic
acid in deionized water (solvent A) and 1% formic acid in acetonitrile (solvent B). The solvent gradient
changed from 6% to 10% solvent B over 20 min, 10% to 13% solvent B over 5 min, 13% to 15% solvent B
over 5 min, 15% to 10% in 10 min, 10% to 6% in 5 min and then maintained isocratically for 5 min.
Chromatograms were recorded at 280 nm. The mass spectrometer was fitted to an atmospheric pressure
electrospray ionization (ESI) source, which operated in negative ion mode. Capillary voltage was set
to 3500 V, with nebulizing gas flow rate of 12 h/L, drying gas temperature of 350 ◦C and nebulizer
pressure of 45 psi. Mass spectrometry data were acquired in scan mode (mass range m/z 100–1000).
Data acquisition and analysis were carried out in an Agilent ChemStation.
An Agilent 1200 series liquid chromatographic system (Agilent Technologies) equipped with
a quaternary pump, column oven, autosampler and DAD was used to quantify the identified
polyphenols in soluble cocoa products by high-performance liquid chromatography (HPLC–DAD).
The chromatographic conditions (column, guard column, binary gradient, injection volume, etc.) were
as described above. For quantitative analysis the external standard method was used. Samples were
prepared and analyzed in triplicate and the results were expressed as the mean value.
2.3. Subjects and Study Design
The study protocol was conducted in accordance with the ethical recommendations of the
Declaration of Helsinki and approved by the Ethics Committee of Hospital Universitario Puerta de
Hierro in Majadahonda (Madrid, Spain) (ACT ID 256, 28th of June 2010; Project Identification Code
AGL2015-69986-R). Recruitment of volunteers was carried out through placing advertisements at the
Institute of Food Science, Technology and Nutrition (ICTAN).
The study was carried out in thirteen healthy subjects (3 men and 10 women); the mens’ average
age and body mass index were 26.67 ± 3.21 year and 22.47 ± 2.97 kg/m2, respectively, and womens’
were 32.60 ± 9.85 year and 23.36 ± 3.73 kg/m2, respectively. They were non-smoker, non-vegetarian,
non-pregnant women, who were not taking any medication or nutritional supplements, and were
not suffering from any chronic pathology or gastrointestinal disorder. The sample size was estimated
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attending to similar previous bioavailability studies [4,16]. The volunteers gave their informed consent
prior to participation.
The present randomized, single-blind study was carried out at the Human Nutrition Unit (HNU)
of the Institute of Food Science, Technology and Nutrition (ICTAN). Volunteers attended the HNU on
two days, separated by two weeks. Three days previous to each visit, participants were instructed
not to consume cocoa products (chocolate, soluble cocoa, etc.), juices, tea, wine, grape must, oranges,
tangerines, apples, grapes, strawberries or other berries, beets, onions, soybeans and soy derivatives.
In addition, volunteers were asked to complete a 24 h food intake recall the day before they attended
the HNU in order to monitor any possible food restriction incompliance.
On each intervention day, volunteers arrived at the HNU after an overnight fast. Prior to the intake
of the soluble cocoa product, a nurse inserted a cannula in the cubital vein of the non-prevailing arm of
the volunteers and blood samples were collected into EDTA-coated tubes at baseline (t = 0) and 0.5, 1,
2, 3, 4, 6, and 8 h after consuming the corresponding cocoa product. The soluble cocoa products, either
15 g of CC or 25 g CC-PP, were dissolved in 200 mL of semi-skimmed milk following manufacturer’s
preparation instructions. Plasma was separated by centrifugation (10 min, 3000 rpm, 4 ◦C) and stored
at −80 ◦C until further analysis. Urine samples were collected at different time intervals (t = −2–0, 0–4,
4–8, 8–12, and 12–24 h) in urine collection flasks that contained 0.5 g of ascorbic acid as preservative and
were aliquoted and frozen at −20 ◦C until analysis. A polyphenol-free breakfast, lunch and afternoon
snack were provided 2 h, 4 h, and 8 h after consumption of cocoa products, and water and isotonic
beverages were available ad libitum.
2.4. Extraction of Phenolic Metabolites from Biological Samples
A liquid–liquid extraction and protein precipitation with acetonitrile was used to isolate metabolites
from plasma. A 1 mL defrosted plasma sample was mixed with 50 µL of ascorbic acid (0.2 g/mL). After
vortexing the aqueous mixture, it was added drop wise to 750 µL of cold acetonitrile and vortexed for
2 min before centrifuging at 12,000 rpm for 10 min at 4 ◦C. The supernatant was separated, and the
pellet was re-extracted twice more following the same procedure. Supernatants were combined and
reduced to dryness under a stream of nitrogen at 30 ◦C. The dried samples were resuspended in
150 µL of aqueous formic acid (0.1%) containing 10% acetonitrile acidified with 0.1% formic acid and
centrifuged at 4 ◦C for 20 min at 14,000 rpm. The final supernatant was collected, filtered (0.45 µm
pore-size, cellulose-acetate membrane filters, Albet, Dassel (Germany)) and 30 µL were analyzed
by high-performance liquid chromatography coupled to electrospray ionisation and quadrupole
time-of-flight mass spectrometry (HPLC-ESI-QToF-MS). Recoveries of the standards used to quantify
metabolites ranged from 95 to 99%.
Urine samples were diluted with an equivalent volume of Milli-Q water (50%) and centrifuged at
14000 rpm (10 min, 4 ◦C). Supernatants were filtered (0.45 µm pore-size cellulose-acetate membrane
filters) and a 5 µL aliquot was directly injected into the LC-ESI-QToF-MS equipment.
2.5. Metabolite Identification by HPLC-ESI-QToF-MS Analysis
Analyses were performed on an Agilent 1200 series LC system coupled to an Agilent
6530A Accurate-Mass Quadrupole Time-Of-Flight (Q-ToF) with ESI-Jet Stream Technology (Agilent
Technologies). Compounds were separated on a reverse-phase Ascentis Express C18 (15 cm × 3 mm,
2.7 m) column (Sigma-Aldrich Química, Madrid) preceded by a Supelco 55215-U guard column at
30 ◦C. The test samples, either 30 µL of the plasma extract or 5 µL of diluted urine, were injected and
separated using a mobile phase consisting of Milli-Q water (phase A) and acetonitrile (phase B), both
containing 0.1% formic acid, at a flow rate of 0.3 mL/min. The mobile phase was initially programmed
with 90% of solvent A and 10% of B. The elution program increased to 30% of solvent B in 10 min. Then,
the initial conditions (10% solvent B) were recovered in 5 min and maintained for 5 min. The Q-ToF
acquisition conditions were as follows: drying gas flow (nitrogen, purity > 99.9%) and temperature
were 10 L/min and 325 ◦C, respectively; sheath gas flow and temperature were 6 L/min and 250 ◦C,
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respectively; nebulizer pressure was 25 psi; cap voltage was 3500 V and nozzle voltage was 500 V. Mass
range selected was from 100 up to 970 m/z in negative mode and fragmentor voltage of 150 V. Data
were processed in a Mass Hunter Workstation Software.
Due to the lack of standards for certain phase II metabolites, they were tentatively quantified
using the calibration curves of their corresponding phenolic precursors. Thus, epicatechin was
used to quantify epicatechin and 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (DHPVL) derivatives and
3,4-dihydroxyphenylpropionic acid to quantify phenylvaleric acid derivatives. The rest of microbial
metabolites identified, derivatives of hydroxyphenylpropionic, hydroxyphenylacetic, hydroxybenzoic
and hippuric acids, were quantified using their respective commercially available standards. Urine
concentration of the excreted metabolites was normalized by the volume excreted in each studied
interval. A linear response was obtained for all the standard curves (from 1 to 1,000 nM), as checked
by linear regression analysis. Calibration curves were freshly prepared in a pool of both plasma
and urine due to matrix effects. Limits of detection and quantification in plasma ranged from 1 to
5 nM and from 2 to 8 nM, respectively, while limits of detection and quantification in urine ranged
from 2.5 to 30 nM and from 50 to 90 nM, respectively. The inter- and intra-day precision of the assay
(as the coefficient of variation, ranging from 2.5 to 9.5%) were considered acceptable and allowed the
quantification of phenolic compounds and their metabolites (quantified as equivalents of the respective
parent molecules). The recovery ranged between 96% and 103% in plasma and between 92% and 97%
in urine samples.
2.6. Nutrikinetic and Statistical Analysis
Statistical analyses were carried out using the program SPSS (version 23.0, SPSS, Inc., IBM
Company, New York, NY, USA). Significant differences between metabolites excreted in urine after
consumption of CC and CC-PP cocoa products were evaluated based on non-parametric Wilcoxon test
(p < 0.05). To determine the absorption and elimination of epicatechin metabolites after consumption of
the soluble cocoa products, metabolite nutrikinetics were studied using the pharmacokinetic functions
of Microsoft Excel, calculating the maximum concentration (Cmax), area under curve (AUC) and time
to reach maximum concentration (Tmax). Data are expressed as mean ± standard deviation.
3. Results
3.1. Phenolic Content of Soluble Cocoa Products
The total polyphenolic content of both cocoa products, according to the Folin–Ciocalteau assay,
was 21.70 and 25.63 µg gallic acid equivalents (GAE)/g in the conventional (CC) and flavanol-rich
(CC-PP) soluble cocoa products, respectively.
In addition, the phenolic composition of both cocoa products was analyzed by HPLC-DAD.
The 200 mL serving prepared from 15 and 25 g of CC and CC-PP products, respectively, provided
68.2 and 235.1 µmoles (19.80 and 68.25 mg) of flavan-3-ols, respectively (Table 1; Table S1; Figure S1).
As expected, the amount of flavanols was higher in the phenol-enriched CC-PP product than in the
conventional cocoa (CC), contrary to the results obtained by the Folin-Ciocalteau assay. Epicatechin
was the most abundant monomer in both products (43.2% and 42.1% of the total polyphenols in CC
and CC-PP, respectively) compared to catechin (24.2% and 19.4% of the total polyphenols in CC and
CC-PP, respectively). Regarding dimeric procyanidins, procyanidin B2 (PB2) was present in higher
concentrations than catechin, with lower amounts of procyanidin B1 (PB1) (3.0–8.5% of the total
polyphenols in CC and CC-PP, respectively).
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Table 1. Phenolic composition of cocoa products (conventional soluble cocoa -CC- and flavanol-rich
soluble cocoa -CC-PP-) determined by high-performance liquid chromatography-diode array
(HPLC-DAD).
Flavanols CCmg/g d.m. (%)
CC-PP
mg/g d.m. (%)
Epicatechin 0.57 ± 0.07 (43.2%) 1.15 ± 0.06 (42.1%)
Catechin 0.32 ± 0.03 (24.2%) 0.53 ± 0.04 (19.4%)
Procyanidin B1 0.04 ± 0.02 (3.0%) 0.23 ± 0.02 (8.5%)
Procyanidin B2 0.39 ± 0.05 (29.6%) 0.82 ± 0.06 (30.0%)
Total Flavanols 1.32 ± 0.17 (100%) 2.73 ± 0.18 (100%)
Expressed in mg per gram of dry matter (d.m. 6.5% CC and 6.7% CC-PP moisture). Values in parenthesis represent
the percentage of total flavanols quantified by high-performance liquid chromatography (HPLC). Mean ± standard
deviation (n = 3).
3.2. LC-ESI-QToF-MS Identification of Flavanols and Metabolites in Plasma and Urine
Table 2 shows the retention time (RT), molecular formula, accurate mass of the quasimolecular
ion [M-H]− after negative ionization, MS2 fragments and location (U: urine or P: plasma) of the main
compounds identified in plasma and urine samples by LC-ESI-QToF-MS. Characterization of the
identified compounds was supported by commercial standards and/or previously published results.
Table 2. High-performance liquid chromatography coupled to electrospray ionisation and quadrupole
time-of-flight mass spectrometry (HPLC-ESI-QToF-MS) identification of flavanol metabolites detected









Epicatechin-3′-glucuronide 7.8 C21H22O12 465.1038 289 P, U
Epicatechin-3′-methoxy-glucuronide 8.0 C22H24O12 479.1195 303 U
Epicatechin-3′-sulfate 9.8 C15H14O9S 369.0286 289 P, U
Epicatechin-methoxy-sulfate (isomer 1) 11.0 C16H16O9S 383.0442 303 P, U
Epicatechin-methoxy-sulfate (isomer 2) 11.7 C16H16O9S 383.0442 303 P, U
Epicatechin-methoxy-sulfate (isomer 3) 12.3 C16H16O9S 383.0442 303 U
Phenyl-γ-Valerolactone (PVL) derivatives
5-(3′,4′-Dihydroxyphenyl)-γ-valerolactone
(DHPVL) 10.8 C11H12O4 207.0663 163 P, U
5-(3′-Hydroxyphenyl)-γ-valerolactone-4′-glucuronide
(HPVL-4′-glucuronide) 7.4 C17H20O10 383.0984 207;163 U
5-(4′-Hydroxyphenyl)-γ-valerolactone-3′-glucuronide
(HPVL-3′-glucuronide) 8.4 C17H20O10 383.0984 207;163 P, U
5-(Hydroxyphenyl)-γ-valerolactone-sulfate
(HPVL-sulfate) 12.0 C11H12O7S 287.0231 207;163 P, U
5-Phenyl-γ-valerolactone-methoxy-glucuronide
(PVL-methoxy-glucuronide) 8.6 C18H22O10 397.1140 221 P, U
5-Phenyl-γ-valerolactone-methoxy-sulfate
(PVL-methoxy-sulfate) 12.0 C12H14O7S 301.0387 221 U
5-(3′-Hydroxyphenyl)-γ-valerolactone (HPVL) 11.6 C11H12O3 191.0714 147 U
5-Phenyl-γ-valerolactone-3′-glucuronide
(PVL-3′-glucuronide) 9.4 C17H20O9 367.1035 191 U
5-Phenyl-γ-valerolactone-3′-sulfate
(PVL-3′-sulfate) 11.7 C11H12O6S 271.0282 191 P, U
Phenylvaleric acid derivatives
4-Hydroxy-5-(3′,4′-dihydroxyphenyl)valeric acid
(HDHPVA) 5.5 C11H14O5 225.0768 179 U
4-Hydroxy-5-(hydroxyphenyl)valeric
acid-glucuronide (HHPVA-glucuronide) 5.1 C17H22O11 401.1089 225 U
4-Hydroxy-5-(hydroxyphenyl)valeric acid-sulfate
(HHPVA-sulfate) 7.3 C11H14O8S 305.0337 225 P, U










3,4-Dihydroxyphenylpropionic acid 8.5 C9H10O4 181.0506 137;122 P, U
3-Methoxy-4-hydroxyphenylpropionic acid 10.8 C10H12O4 195.0663 137 P, U
3-Hydroxyphenylpropionic acid 11.1 C9H10O3 165.0557 121 P, U
3,4-Dihydroxyphenylacetic acid 5.6 C8H8O4 167.0350 123 P, U
3-Methoxy-4-hydroxyphenylacetic acid 6.5 C9H10O4 181.0506 137 U
3-Hydroxyphenylacetic acid 7.4 C8H8O3 151.0401 107 U
Ferulic acid 12.3 C10H10O4 193.0506 134 P, U
Isoferulic acid 15.4 C10H10O4 193.0506 134 U
3,4-Dihydroxybenzoic acid 3.8 C7H604 153.0193 109 P, U
4-Hydroxyhippuric acid 10.7 C9H9O4N 194.0459 100 P, U
3-Hydroxyhippuric acid 14.1 C9H9O4N 194.0459 150 P, U
Hydroxybenzoic acid 6.3 C7H6O3 137.0244 93 P, U
No un-metabolized compounds originally present in both cocoa products (CC and CC-PP) were
detected in plasma and urine samples. Phase II derivatives of epicatechin were detected in biological
fluids after consuming both types of soluble cocoa products. In particular, glucuronidated epicatechin
was assigned to the chromatographic peak that eluted at 7.8 min, with a quasimolecular ion at m/z
465.1038 and fragment ion at m/z 289 corresponding to epicatechin, present in both plasma and urine.
Based on previous studies [4,16], this peak was assigned as epicatechin-3′-glucuronide.
Related to glucuronide derivatives, the presence of the epicatechin-methoxy-glucuronide
derivative ([M-H]− at m/z 479.1195 and fragment ion at m/z 303 corresponding to methoxy derivative
of epicatechin) was confirmed in urine. This compound showed a higher RT (8.0 min) than
that described for the glucuronidated derivative (RT at 7.8 min), consistent with the lipophilicity
that the methyl group provides to the molecule. This metabolite was tentatively assigned as
epicatechin-3′-methoxy-glucuronide based on the study carried out by Actis-Goretta et al. [16].
Subsequently, the chromatographic peak present in both plasma and urine at 9.8 min was assigned to
epicatechin-3′-sulfate, thanks to its MS spectrum ([M-H]− at m/z 369.0286 and fragment ion at m/z 289
corresponding to epicatechin). This metabolite has already been described after consumption of dark
chocolate [16] and cocoa [4]. Three methoxy-sulfated isomers at 11.0, 11.7 and 12.3 min ([M-H]− at
m/z 383.0442 and fragment ion at m/z 303) were tentatively identified as epicatechin-methoxy-sulfate
(isomer 1, isomer 2, and isomer 3), based on previous studies [4,16]. The two metabolites that eluted
earlier (at 11.0 and 11.7 min) have been detected in both plasma and urine, while the third metabolite
at 12.3 min was only detected in urine.
After the intake of soluble cocoa products, derivatives of phenyl-γ-valerolactone are
important compounds formed as a result of the microbial metabolism of flavanols [17]. Thus,
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (DHPVL) was identified in both plasma and urine at
RT 10.8 min a quasimolecular ion at m/z 207.0663 and fragment ion at m/z 163, in agreement
with the pattern fragmentation already described by other authors [17,18]. In addition, phase
II derivatives of DHPVL were detected. Two glucuronidated (RT at 7.4 and 8.4 min) and one
sulfated (RT 12.0 min) derivatives of DHPVL were detected in both plasma and urine, except the
glucuronidated metabolite at RT 7.4 min, not found in plasma. Quasimolecular ions at m/z 383.0984
and 287.0231 were compatible with glucuronide and sulfate derivatives, respectively, in addition
to common fragment ions at m/z 207 and 163 corresponding to DHPVL. Finally, chromatographic
peaks at 7.4, 8.4, and 12.0 min were assigned as 5-(3′-hydroxyphenyl)-γ-valerolactone-4′-glucuronide
(HPVL-4′-glucuronide), 5-(4′-hydroxyphenyl)-γ-valerolactone-3′-glucuronide (HPVL-3′-glucuronide),
and 5-(4′-hydroxyphenyl)-γ-valerolactone-sulfate (HPVL-sulfate), respectively, based on Actis-Goretta
et al. [16], who used similar chromatographic conditions and observed that the glucuronidated and
sulfated isomers of epicatechin at the C4′ position elute earlier than those at the C3′ position, contrary to
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what occurs with methoxy derivatives [16]. Likewise, results reported by Ottaviani et al. [8] confirmed
the identity of these metabolites.
Methoxy derivatives of DHPVL were also identified, in particular, 5-phenyl-γ-valerolactone-
methoxy-glucuronide (PVL-methoxy-glucuronide) was assigned to the chromatographic peak that
eluted at 8.6 min, with a quasimolecular ion at m/z 397.1140 and fragment ion at m/z 221 corresponding
to 5-phenyl-γ-valerolactone-methoxy, found in plasma and urine. The chromatographic peak present
in urine at 12.0 min was assigned to 5-phenyl-γ-valerolactone-methoxy-sulfate (PVL-methoxy-sulfate)
thanks to its MS spectrum, ([M-H]− at m/z 301.0387 and fragment ion at m/z 221).
Based on the preferred dehydroxylation route in the C4′ of ring B described for flavanols [19], the
presence of 5-(3′-hydroxyphenyl)-γ-valerolactone (HPVL) and its phase II derivatives was postulated.
The search for the [M-H]− ion at m/z 191.0714 yielded a peak at RT 11.6 min supported by the fragment ion
at m/z 147, which allowed the identification of HPVL. Likewise, the peaks at RT 9.4 and 11.7 min showed a
consistent fragmentation pattern with a glucuronidated derivative ([M-H]− at m/z 367.1035 and fragment
at m/z 191) and a sulfated derivative ([M-H]− at m/z 271.0282 and fragment at m/z 191), respectively.
These compounds have been tentatively identified as 5-(phenyl)-γ-valerolactone-3′-glucuronide
(PVL-3′-glucuronide) and 5-(phenyl)-γ-valerolactone-3′-sulfate (PVL-3′-sulfate), respectively.
Phenyl-γ-valerolactones evolve to phenylvaleric acid derivatives. Thus, 4-hydroxy-5-(3′,4′-
dihydroxyphenyl)valeric acid (HDHPVA) was assigned to the chromatographic peak at RT 5.5 min
detected in urine, due to its quasimolecular ion [M-H]− at m/z 225.0768 and MS/MS fragmentation
pattern coinciding with that described by Stoupi et al. [20], who identified this compound after in vitro
fermentation of epicatechin and PB2 (fragment ion at m/z 179). Likewise, its glucuronidated derivative
([M-H]− at m/z 401.1089 and fragment ion at m/z 225, corresponding to its precursor HDHPVA) and
sulfated derivative ([M-H]− at m/z 305.0337 and fragment ion at m/z 225) were identified, eluting at 5.1
and 7.3 min, respectively. While the sulfated metabolite was detected in both plasma and urine, the
glucuronidated derivative was only detected in urine.
Finally, derivatives of hydroxyphenylpropionic, hydroxyphenylacetic, hydroxybenzoic, and
hydroxyhippuric acids were detected in plasma and urine samples (Table 2).
3.3. Quantification of Plasma Metabolites and Nutrikinetic Parameters
Out of the 30 metabolites identified after consumption of the two soluble cocoa products, 8 and
10 were detected in plasma after CC and CC-PP consumption, respectively, although only 7 and
10 metabolites, respectively, showed levels above the limit of quantification. The kinetics of plasma
appearance and clearance of these metabolites up to 8 h post-intake are represented in Figure 1.
Nutrikinetic parameters are summarized in Table 3.
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Figure 1. Plasma concentrations of the identified metabolites after consuming a conventional soluble 
cocoa product (CC) and a flavanol-rich soluble cocoa product (CC-PP) containing 19.80 and 68.25 mg 
of flavanols, respectively. (a) Epicatechin-3′-glucuronide; (b) epicatechin-3′-sulfate; (c) epicatechin-
methoxy-sulfate (isomer 1); (d) epicatechin-methoxy-sulfate (isomer 2); (e) 5-(3′,4′-dihydroxyphenyl)-
γ-valerolactone (DHPVL); (f) 5-(4′-hydroxyphenyl)-γ-valerolactone-3′-glucuronide (HPVL-3′-
glucuronide); (g) 5-(hydroxyphenyl)-γ-valerolactone-sulfate (HPVL-sulfate); (h) 5-phenyl-γ-
valerolactone-methoxy-glucuronide (PVL-methoxy-glucuronide); (i) 5-phenyl-γ-valerolactone-3′-
sulfate (PVL-3′-sulfate) and (j) 4-hydroxy-5-(hydroxyphenyl)valeric acid-sulfate (HHPVA-sulfate). 
Results represent concentration (µM) as mean ± standard deviation (n = 13). The lower part of the 






































































































































































































Figure 1. Plasma concentrations of the id ntified metabolites af r consumi g a co ventional soluble c coa
product (CC) and a flav ol-rich soluble ocoa product (CC-PP) containing 19.80 and 68.25 mg of flavanols,
respecti ely. (a) Epicatechin-3′-glucuronide; (b) epi atechin-3′-sulfate; (c) epicatechin- methoxy-sulfate
(isomer 1); (d) epicatechin-methoxy-sulfate (isomer 2); (e) 5-(3′,4′-dihydroxyphenyl)- γ-valerolacto e
(DHPVL); (f) 5-(4′-hydroxyphenyl)-γ-valerolactone-3′-glucuronide (HPVL-3′-glucuronide);
(g) 5-(hydroxyphenyl)-γ-valerolactone-sulfate (HPVL-sulfate); (h) 5-phenyl-γ- valerolactone-
methoxy-glucuronide (PVL-methoxy-glucuronide); (i) 5-phenyl-γ-valerolactone-3′- sulfate (PVL-3′-sulfate)
and (j) 4-hydroxy-5-(hydroxyphenyl)valeric acid-sulfate (HHPVA-sulfate). Results represent concentration
(µM) as mean ± standard deviation (n = 13). The lower part of the error bars is not displayed for the sake
of clarity.
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Un-metabolized flavanols were not detected in plasma after the consumption of both products (CC
and CC-PP). Phase II derivatives of flavanols, epicatechin-3′-glucuronide, epicatechin-3′-sulfate and
epicatechin-methoxy-sulfate (isomer 1) after CC and CC-PP intake, and epicatechin-methoxy-sulfate
(isomer 2) after CC-PP intake, were detected in plasma. Concentrations of these phase II derivatives
showed a rapid increase between 1 and 1.5 h after the consumption soluble cocoa products, whilst
their clearance was slow, maintaining or even showing a second maxima between 3 and 6 h, with
subsequent clearance at 8 h post-intake (Figure 1).
Table 3. Nutrikinetic parameters of metabolites detected in human plasma after consuming a
conventional soluble cocoa product (CC) and a flavanol-rich soluble cocoa product (CC-PP) containing
19.80 and 68.25 mg of flavanols, respectively. Values represent mean ± standard deviation (n = 13).















glucuronide 0.025 ± 0.001 1.5 ± 0.5 0.072 ± 0.028 0.037 ± 0.001 1.4 ± 0.8 0.110 ± 0.066 <0.05 N.S. N.S.
Epicatechin-3′-sulfate 0.026 ± 0.003 1.0 ± 0.1 0.101 ± 0.023 0.042 ± 0.004 1.2 ± 0.5 0.109 ± 0.076 N.S. N.S. N.S.
Epicatechin-methoxy-
sulfate (isomer 1) 0.031 ± 0.003 1.3 ± 0.6 0.122 ± 0.025 0.041 ± 0.002 1.1 ± 0.6 0.173 ± 0.107 <0.05 N.S. N.S.
Epicatechin-methoxy-
sulfate (isomer 2) N.D. 0.041 ± 0.004 1.3 ± 0.5 0.145 ± 0.107 <0.05 <0.05 <0.05
Microbial metabolites
DHPVL 0.035 ± 0.008 6.0 ± 1.6 0.124 ± 0.073 0.037 ± 0.007 5.5 ± 1.4 0.192 ± 0.029 N.S. N.S. N.S.
HPVL-3′-glucuronide 0.031 ± 0.004 5.6 ± 0.8 0.106 ± 0.021 0.357 ± 0.200 5.0 ± 1.2 1.433 ± 0.727 <0.05 N.S. <0.05
HPVL-sulfate 0.336 ± 0.240 5.3 ± 2.4 1.150 ± 0.742 0.332 ± 0.161 4.9 ± 1.2 1.384 ± 0.648 N.S. N.S. N.S.
PVL-methoxy-
glucuronide 0.022 ± 0.001 5.3 ± 1.0 0.078 ± 0.032 0.027 ± 0.003 5.6 ± 1.3 0.091 ± 0.059 <0.05 N.S. N.S.
PVL-3′-sulfate b Traces (4–6) a 0.039 ± 0.014 5.2 ± 2.2 0.161 ± 0.105 <0.05 <0.05 <0.05
HHPVA-sulfate N.D. 0.037 ± 0.008 6.3 ± 1.8 0.167 ± 0.068 <0.05 <0.05 <0.05
AUC: area under the curve; DHPVL: 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone; HPVL: 5-(3′-
hydroxyphenyl)-γ-valerolactone; PVL: 5-phenyl-γ-valerolactone; HDHPVA: 4-hydroxy-5-(3′,4′-
dihydroxyphenyl)valeric acid; N.D.: Not detected; N.S.: Non-significant differences; p values were
assessed using the general linear model of variance for repeated measures. a Range where the metabolite showed
the highest value. b No pharmacokinetic parameters of these metabolites were determined because they were
present at trace levels.
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (DHPVL) and its phase II derivatives;
HPVL-3′-glucuronide, HPVL-3′-sulfate, PVL-methoxy-glucuronide, and PVL-3′-sulfate, formed
the main group of metabolites detected in plasma (Figure 1). The plasmatic profile of these metabolites
showed maxima concentrations between 4.9 and 6.3 h (Tmax) post-intake, except PVL-3′-sulfate after
CC intake which appeared at traces level (Table 3). HPVL-3′-sulfate was the predominant metabolite
after CC and CC-PP intake, showing Cmax value of 1.150 and 1.384 µM, respectively, followed by
HPVL-3′-glucuronide with Cmax ranging from 0.106 to 1.433 µM, respectively (Table 3).
A sulfated derivative of phenylvaleric acid, HHPVA-sulfate, was also detected in plasma but only
after CC-PP intake with similar kinetic behavior than derivatives of phenyl-γ-valerolactones, with
maxima concentration at 6.3 h post-intake (Figure 1).
In general, metabolites’ Cmax after CC consumption were significantly lower than after CC-PP
intake (p < 0.05), consistent with the higher content of flavanols ingested with the polyphenol-rich cocoa.
3.4. Quantification of Urinary Metabolites
Up to 29 and 30 metabolites were quantified in 24 h urine samples after CC and CC-PP consumption,
respectively (Table 4; Table 5). Neither epicatechin nor PB2 dimer was detected in urine in any of
the interventions.
Phase II derivatives of epicatechin were preferentially excreted in the first two sampling intervals
(0–4 and 4–8 h) after the ingestion of both soluble products. In the range of 0–4 h, the excretion of these
metabolites was 58.3% and 62.0% (CC and CC-PP, respectively) of the total phase II derivatives of
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epicatechin excreted in urine; these percentages decreased to 36.0% and 34.8% in the second interval
(4–8 h). Sulfated and/or methoxysulfated derivatives contributed 93% in both interventions with CC
and CC-PP, showing that sulfation was the preferential route of biotransformation according to what
was previously observed in the plasma. This group of metabolites represented 35.9% and 31.0% of the
total urinary metabolites after CC and CC-PP intake, respectively.
DHPVL and its phase II derivatives, HPVL-4′-glucuronide, HPVL-3′-glucuronide and
HPVL-sulfate, along with PVL-methoxy-glucuronide, PVL-methoxy-sulfate, PVL-3′-glucuronide
and PVL-3′-sulfate conformed the most important group of metabolites quantified in urine after
the ingestion of both soluble cocoa products. This group was largely excreted between 4 and 8 h
post-intake and represented the 54.4% and 56.1% of the total urinary metabolites after CC and CC-PP
intake, respectively. Excretion of HPVL-sulfate added up to 9.9 and 31.32 µmoles in 24 h followed by
PVL-3′-sulfate (2.0 µmoles and 7.8 µmoles) after CC and CC-PP intake, respectively, evidencing that
the sulfation was the preferential biotransformation pathway.
Regarding phenylvaleric acid derivatives, HHPVA-sulfate and HHPVA-glucuronide were also
excreted preferentially between 4 and 8 h post-intake, accounting for 9.7% and 12.9% of the total
urinary metabolites after CC and CC-PP intake, respectively.
Finally, derivatives of hydroxyphenylpropionic, hydroxyphenylacetic, and hydrophenylbenzoic
acids, along with hydroxyhippuric acid, were present in basal urine before cocoa product intake but
their levels increased after CC and CC-PP consumption (0–24 h), peaking between 4 and 8 h compared
to baseline values (Table 4). However, there was little difference in the total content excreted for this
group of metabolites (13.1 µmoles and 15.8 µmoles after CC and CC-PP consumption, respectively)
despite the large difference of polyphenol intake between both soluble cocoa products (68.2 µmoles of
CC and 235 µmoles of CC-PP). For this reason, this group of metabolites was not taken into account to
determine flavanols recovery.
Attending to these results, it may be summarized that the total amount of metabolites in 24 h urine
after the intake of a single serving of CC and CC-PP beverages added up to 24.1µmol and 81.3 µmoles
(Tables 4 and 5), respectively, corresponding to 35.3% and 34.6% of the 68.2 and 235.1 µmoles of
polyphenols consumed, respectively.
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Table 4. Metabolites excreted in urine (from 0 to 24 h) by healthy volunteers after consumption of the conventional soluble cocoa product (CC) containing 19.80 mg
of flavanols.
Metabolite Basal (µmol) 0–4 h (µmol) 4–8 h (µmol) 8–12 h (µmol) 12–24 h (µmol) Total (µmol)
Intestinal Absorption Epicatechin-3′-glucuronide N.D. 0.355 ± 0.071 0.267 ± 0.059 <L.Q. <L.Q. 0.622 ± 0.130 *
Epicatechin-3′-methoxy-glucuronide N.D. <L.Q. <L.Q. N.D. N.D. <L.Q. *
Epicatechin-3′-sulfate N.D. 1.323 ± 0.236 1.018 ± 0.178 0.076 ± 0.025 <L.Q. 2.417 ± 0.439 *
Epicatechin-methoxy-sulfate (isomer 1) N.D. 2.717 ± 0.457 1.300 ± 0.197 0.154 ± 0.031 0.257 ± 0.114 4.428 ± 0.800 *
Epicatechin-methoxy-sulfate (isomer 2) N.D. 0.181 ± 0.032 0.247 ± 0.030 <L.Q. <L.Q. 0.428 ± 0.062 *
Epicatechin-methoxy-sulfate (isomer 3) N.D. 0.473 ± 0.089 0.285 ± 0.036 <L.Q. N.D. 0.758 ± 0.125 *
Total—intestinal absorption N.D. 5.049 ± 0.885 3.117 ± 0.500 0.230 ± 0.056 0.257 ± 0.114 8.653 ± 1.556 *
Colonic Absorption DHPVL <L.Q. <L.Q. 0.146 ± 0.032 <L.Q. <L.Q. 0.146 ± 0.032 *
HPVL N.D. N.D. <L.Q. <L.Q. <L.Q. <L.Q. *
HDHPVA N.D. N.D. <L.Q. <L.Q. <L.Q. <L.Q.
HPVL-4′-glucuronide <L.Q. <L.Q. 0.111 ± 0.049 <L.Q. <L.Q. 0.111 ± 0.049 *
HPVL-3′-glucuronide <L.Q. <L.Q. 0.497 ± 0.204 0.103 ± 0.028 <L.Q. 0.600 ± 0.232 *
HPVL-sulfate 0.143 ± 0.064 0.456 ± 0.193 5.638 ± 1.922 1.945 ± 0.647 1.744 ± 0.374 9.926 ± 3.200 *
PVL-methoxy-glucuronide <L.Q. <L.Q. 0.111 ± 0.039 <L.Q. <L.Q. 0.111 ± 0.039 *
PVL-methoxy-sulfate <L.Q. N.D. 0.085 ± 0.031 <L.Q. <L.Q. 0.085 ± 0.031 *
PVL-3′glucuronide N.D. <L.Q. 0.233 ± 0.155 0.126 ± 0.078 0.079 ± 0.022 0.438 ± 0.255
PVL-3′-sulfate <L.Q. <L.Q. 0.860 ± 0.385 0.456 ± 0.284 0.375 ± 0.133 1.691 ± 0.802 *
HHPVA-glucuronide N.D. N.D. N.D. N.D. N.D. N.D. *
HHPVA-sulfate 0.089 ± 0.055 0.076 ± 0.055 1.112 ± 0.397 0.565 ± 0.171 0.503 ± 0.152 2.345 ± 0.830 *
Total—colonic absorption 0.232 ± 0.119 0.532 ± 0.248 8.793 ± 3.214 3.195 ± 1.208 2.701 ± 0.681 15.453 ± 5.470 *
Other microbial metabolites 3,4-Dihydroxyphenylpropionic acid 0.117 ± 0.024 0.217 ± 0.051 0.243 ± 0.039 0.074 ± 0.017 0.215 ± 0.016 0.866 ± 0.148
3-Methoxy-4-hydroxyphenylpropionic acid 0.104 ± 0.027 0.144 ± 0.044 <L.Q. <L.Q. <L.Q. 0.248 ± 0.071
Hydroxyphenylpropionic acid 0.118 ± 0.023 0.226 ± 0.046 0.259 ± 0.043 0.077 ± 0.018 0.203 ± 0.025 0.883 ± 0.154
3,4-Dihydroxyphenylacetic acid 0.094 ± 0.032 0.648 ± 0.505 0.556 ± 0.379 0.094 ± 0.033 0.133 ± 0.020 1.525 ± 0.974
3-Methoxy-4-hydroxyphenylacetic acid 0.103 ± 0.014 0.099 ± 0.054 0.093 ± 0.028 <L.Q. 0.103 ± 0.022 0.398 ± 0.118
Hydroxyphenylacetic acid 0.369 ± 0.077 0.408 ± 0.084 0.605 ± 0.092 0.225 ± 0.052 0.600 ± 0.100 2.208 ± 0.328
Ferulic acid <L.Q. <L.Q. 0.094 ± 0.009 0.099 ± 0.059 N.D. 0.193 ± 0.068
Isoferulic acid 0.170 ± 0.137 0.086 ± 0.028 0.096 ± 0.040 0.088 ± 0.069 0.082 ± 0.016 0.522 ± 0.290
Protocatechuic acid 0.161 ± 0.071 0.227 ± 0.142 0.373 ± 0.237 0.094 ± 0.047 0.104 ± 0.044 0.959 ± 0.217 *
Hydroxyhippuric acid 0.821 ± 0.251 0.864 ± 0.154 1.171 ± 0.387 0.242 ± 0.067 0.995 ± 0.316 4.093 ± 1.175
Hydroxyhippuric acid 0.075 ± 0.031 0.085 ± 0.043 0.082 ± 0.055 0.075 ± 0.031 0.077 ± 0.046 0.394 ± 0.206
Hidroxybenzoic acid 0.188 ± 0.041 0.145 ± 0.027 0.200 ± 0.051 0.070 ± 0.018 0.195 ± 0.025 0.798 ± 0.162
Total other microbial metabolites 2.320 ± 0.728 3.149 ± 1.178 3.772 ± 1.360 1.138 ± 0.411 2.707 ± 0.630 13.086 ± 3.911
INTESTINAL + COLONIC METABOLITES 0.232 ± 0.119 5.581 ± 1.133 11.910 ± 3.714 3.425 ± 1.264 2.958 ± 0.795 24.106 ± 7.026
HDHPVA: 4-hydroxy-5-(3′,4′-dihydroxyphenyl)valeric acid; DHPVL: 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone; HPVL: 5-(3′-hydroxyphenyl)-γ-valerolactone; PVL: 5-phenyl-
γ-valerolactone. * Significant differences respect to CC-PP intervention was observed based on non-parametric Wilcoxon test at p < 0.05. Values represent mean ± standard
deviation (n = 13). N.D.: not detected; <L.Q. lower than quantification limit.
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Table 5. Metabolites excreted in urine (from 0 to 24 h) by healthy volunteers after consumption of the flavanol-rich soluble cocoa product (CC-PP) containing 68.25 mg
of flavanols.
Metabolite Basal (µmol) 0–4 h (µmol) 4–8 h (µmol) 8–12 h (µmol) 12–24 h (µmol) Total (µmol)
Intestinal Absorption Epicatechin-3′-glucuronide N.D. 0.958 ± 0.272 0.695 ± 0.190 <L.Q. <L.Q. 1.653 ± 0.462 *
Epicatechin-3′-methoxy-glucuronide N.D. 0.121 ± 0.036 <L.Q. <L.Q. N.D. 0.121 ± 0.036 *
Epicatechin-3′-sulfate N.D. 3.627 ± 0.797 3.572 ± 0.662 0.158 ± 0.038 <L.Q. 7.357 ± 1.523 *
Epicatechin-methoxy-sulfate (isomer 1) N.D. 8.642 ± 1.434 3.277 ± 0.644 0.330 ± 0.095 0.232 ± 0.070 12.481 ± 2.243 *
Epicatechin-methoxy-sulfate (isomer 2) N.D. 0.566 ± 0.152 0.557 ± 0.120 0.077 ± 0.021 <L.Q. 1.200 ± 0.293 *
Epicatechin-methoxy-sulfate (isomer 3) N.D. 1.702 ± 0.243 0.652 ± 0.148 <L.Q. <L.Q. 2.354 ± 0.402 *
Total—intestinal absorption N.D. 15.616 ± 2.934 8.753 ±1.764 0.565 ± 0.154 0.232 ± 0.070 25.166 ± 4.959 *
Colonic Absorption DHPVL <L.Q. <L.Q. 0.628 ± 0.087 0.174 ± 0.029 0.282 ± 0.082 1.084 ± 0.199 *
HPVL N.D. <L.Q. 0.104 ± 0.041 <L.Q. <L.Q. 0.104 ± 0.041 *
HDHPVA N.D. <L.Q. <L.Q. <L.Q. <L.Q. <L.Q.
HPVL-4′-glucuronide <L.Q. <L.Q. 0.330 ± 0.111 0.550 ± 0.015 0.081 ± 0.025 0.961 ± 0.151 *
HPVL-3′-glucuronide <L.Q. <L.Q. 1.802 ± 0.567 0.274 ± 0.060 0.282 ± 0.130 2.358 ± 0.766 *
HPVL-sulfate 0.332 ± 0.164 1.965 ± 0.636 15.979 ± 2.963 5.386 ± 0.934 7.656 ± 2.125 31.318 ± 6.822 *
PVL-methoxy-glucuronide <L.Q. <L.Q. 0.340 ± 0.074 0.084 ± 0.014 0.131 ± 0.046 0.555 ± 0.134 *
PVL-methoxy-sulfate N.D. <L.Q. 0.177 ± 0.036 <L.Q. <L.Q. 0.177 ± 0.047 *
PVL-3′glucuronide <L.Q. 0.108 ± 0.045 0.521 ± 0.191 0.179 ± 0.063 0.508 ± 0.349 1.316 ± 0.648
PVL-3′-sulfate <L.Q. 0.651 ± 0.389 4.188 ± 1.535 1.223 ± 0.373 1.690 ± 0.572 7.752 ± 2.868 *
HHPVA-glucuronide N.D. <L.Q. 0.714 ± 0.088 0.087 ± 0.019 0.251 ± 0.075 1.052 ± 0.182 *
HHPVA-sulfate 0.089 ± 0.032 0.584 ± 0.223 5.018 ± 1.090 1.798 ± 0.376 1.987 ± 0.566 9.476 ± 2.287 *
Total—colonic absorption 0.421 ± 0.196 3.308 ± 1.293 29.801 ± 6.783 9.755 ± 1.883 12.868 ± 3.970 56.153 ± 14.145 *
Other microbial metabolites 3,4-Dihydroxyphenylpropionic acid 0.213 ± 0.031 0.256 ± 0.027 0.238 ± 0.028 0.109 ± 0.016 0.301 ± 0.029 1.117 ± 0.131
3-Methoxy-4-hydroxyphenylpropionic acid 0.077 ± 0.032 0.175 ± 0.054 <L.Q. <L.Q. 0.199 ± 0.052 0.461 ± 0.138
Hydroxyphenylpropionic acid 0.074 ± 0.013 0.350 ± 0.038 0.356 ± 0.076 0.140 ± 0.041 0.284 ± 0.075 1.204 ± 0.243
3,4-Dihydroxyphenylacetic acid 0.109 ± 0.015 0.751 ± 0.057 0.556 ± 0.096 0.198 ± 0.037 0.539 ± 0.196 2.153 ± 0.401
3-Methoxy-4-hydroxyphenylacetic acid 0.198 ± 0.071 0.188 ± 0.026 0.124 ± 0.050 <L.Q. 0.138 ± 0.016 0.648 ± 0.178
Hydroxyphenylacetic acid 0.585 ± 0.070 0.631 ± 0.140 0.678 ± 0.231 0.434 ± 0.070 0.534 ± 0.143 2.862 ± 0.654
Ferulic acid <L.Q. 0.137 ± 0.092 0.150 ± 0.094 0.151 ± 0.094 0.312 ± 0.290 0.750 ± 0.570
Isoferulic acid <L.Q. 0.164 ± 0.044 0.160 ± 0.066 0.152 ± 0.094 0.210 ± 0.152 0.686 ± 0.356
Protocatechuic acid 0.088 ± 0.014 0.105 ± 0.016 0.113 ± 0.020 0.095 ± 0.040 0.127 ± 0.015 0.528 ± 0.105 *
Hydroxyhippuric acid 0.871 ± 0.264 0.789 ± 0.100 0.579 ± 0.096 0.328 ± 0.063 0.987 ± 0.193 3.554 ± 0.716
Hydroxyhippuric acid 0.086 ± 0.013 0.090 ± 0.009 0.082 ± 0.009 0.075 ± 0.063 0.129 ± 0.017 0.462 ± 0.111
Hidroxybenzoic acid 0.212 ± 0.037 0.396 ± 0.060 0.298 ± 0.036 0.172 ± 0.063 0.302 ± 0.169 1.380 ± 0.365
Total other microbial metabolites 2.513 ± 0.560 4.032 ± 0.663 3.334 ± 0.802 1.854 ± 0.581 4.062 ± 1.347 15.805 ± 3.968
INTESTINAL + COLONIC METABOLITES 0.421 ± 0.196 18.924 ± 4.227 38.554 ± 8.547 10.320 ± 2.037 13.100 ± 4.040 81.319 ± 19.104
HDHPVA: 4-hydroxy-5-(3′,4′-dihydroxyphenyl)valeric acid; DHPVL: 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone; HPVL: 5-(3′-hydroxyphenyl)-γ-valerolactone; PVL: 5-phenyl-
γ-valerolactone. * Significant differences respect to CC-PP intervention was observed based on non-parametric Wilcoxon test at p < 0.05. Values represent mean ± standard
deviation (n = 13). N.D.: not detected; <L.Q. lower than quantification limit.
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4. Discussion
Relevant studies on the absorption and metabolism of flavanols in different cocoa products
have been recently published [3,13,14,21]. However, the particularity of the present work lies in the
realistic dose administered to the participants, following the recommendations of the cocoa product
manufacturer. Furthermore, the present study compares the bioavailability of flavanols in two cocoa
products: one conventional, naturally rich in cocoa (CC) and the other enriched in flavanols (CC-PP).
This enabled us to check if the higher phenol doses administered with CC-PP would alter the kinetics
of appearance, clearance and biotransformation. Furthermore, special attention has been paid to
identify novel microbial metabolites, considering that the identification could contribute to shed light
on the biotransformation pathway of flavanols in cocoa in general terms, and soluble cocoa products
in particular, therefore allowing to further understand the bioactivity of these products.
The results show that flavanols present in soluble cocoa products are partially absorbed and
extensively metabolized, so that most of the metabolites are produced by the intestinal microbiota.
Thus, phenyl-γ-valerolactones and phenylvaleric acid derivatives, mainly as phase II conjugated
metabolites, formed after absorption in the colon, were the predominant metabolites in plasma and
urine, underlying the importance of the microbiota in the metabolism of flavanols (Figure 2).
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Neither un-metabolized epicatechin and catechin nor procyanidins B1 and B2 were detected in the
collected biological fluids in agreement with previous studies [4,11,16,22–25]. Only Schroeter et al. [26]
described the presence of epicatechin and catec in in plasma aft r the ingestion of powdered cocoa
drinks with a high flavanol ontent (917 mg). Flav nols followed two different pa hways: a minor
part of metabolites was subsequently metabolized by ph se II enzymes into sulfated, glucuronidated
and methoxy derivatives in the intestinal epithelium, after ntering the bloodstream, whereas most
flavanols re ched the colon and were transformed by microbial enzymes prior to absorption and
conjug tion in o ph se II metabolites.
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Regarding the compounds identified in the systemic circulation, the present results are in
agreement with those described by Actis-Goretta et al. [16], Ottaviani et al. [4], Borges et al. [21],
and Montagnana et al. [11], who identified glucuronidated, sulfated and methoxy-sulfated derivatives
of epicatechin in plasma. These metabolites were quantified in nM concentrations with Cmax values
from 25 to 31 nM and 37 to 42 nM after CC and CC-PP intake, respectively. As can be seen, there were
no remarkable differences in the plasma concentrations of the major phase II epicatechin derivatives,
in spite of the different intake of polyphenols with both cocoa products (CC, providing 19.80 mg, and
CC-PP, with a total intake of 68.2 mg). In contrast, plasma concentrations as high as ~300 nM were
reported by Actis-Goretta et al. [16] after the ingestion of 154 mg of flavanols in 100 g of dark chocolate,
or up to 590 nM after the intake of 1,100 mg of flavanols in a soluble cocoa product [4]. Mullen et al. [25]
demonstrated the interference of milk proteins in the absorption of flavanols, which might explain the
lower plasmatic level of metabolites described in this study compared to Actis-Goretta et al. [16] or
Ottaviani et al. [4], among others. However, it is noteworthy that these high intakes correspond to
non-realistic doses that are difficult to maintain on a daily basis within a balanced diet. The time that
these metabolites took to reach the maximum concentration in plasma (Tmax), ranged from 1.0 h and
1.5 h with both soluble cocoa products, pointing to the absorption in the proximal gastrointestinal tract,
in agreement with other studies [4,8,24,25,27,28].
On reaching the colon, flavanols undergo microbiota-mediated conversion yielding the 5C-ring
fission metabolites, 5-(hydroxypheynyl)-γ-valerolactones and 5-(hydroxyphenyl)-γ-hydroxyvaleric
acids that appear in plasma preferably as phase II metabolites, being HPVL-sulfate and
HPVL-3′-glucuronide the most abundant metabolites. Cmax of the total amount of these metabolites
was 424 nM and 829 nM after CC and CC-PP intake, respectively, and their Tmax ranged from 5.0 to
6.0 h, distinctive of colon-derived products. These results are in line with those obtained by Ottaviani
et al. [8], who evaluated the absorption, metabolism, distribution, and excretion of radiolabeled and
stereochemically pure [2-14C](-)-epicatechin ([14C]epicatechin) in 8 male volunteers that consumed a
drink containing 207 µmol (60 mg) of flavanols and reported in plasma a total concentration of 588 nM
of this group of metabolites. Recently, Montagnana et al. [11] also has detected phenyl-γ-valerolactone
metabolites (glucuronidated, sulfated and methoxy derivatives) in plasma 4 h after the ingestion of
50 g of 90% cocoa chocolate (7.5 gallic acid equivalents of polyphenols).
There were substantially higher levels of metabolites in urine than plasma. The main urinary
metabolites were epicatechin-methoxy-sulfate (isomer 1) and epicatechin-3′-sulfate along with
epicatechin-methoxy-sulfate (isomer 3), epicatechin-3′-glucuronide and epicatechin-methoxy-sulfate
(isomer 2) followed by epicatechin-3′-methoxy-glucuronide. Sulfated and/or methylsulfated derivatives
of epicatechin represented 92% of this group of metabolites after consumption of both soluble cocoa
products, confirming sulfation as the preferential biotransformation pathway. These results are in
line with previous studies [4,8,16,25] although the proportion of metabolites was dependent on the
amount of epicatechin ingested, so that a greater proportion of sulfated derivatives in all their forms
(sulfated and methoxy-sulfated) was observed at lower doses of epicatechin, as in Mullen et al. [25],
after the intake of 13 mg of flavanols, whereas a higher proportion of glucuronidated derivatives was
observed at higher doses of epicatechin as in Ottaviani et al. [4], who administered 1100 mg of flavanols.
Later Ottaviani et al. [8] detected a balanced amount of glucuronidated and sulfated derivatives of
epicatechin after the intake of 60 mg of epicatechin. Phase II derivatives of epicatechin were excreted
mainly in the initial 0–4 h urine collection period, followed by the interval 4–8 h and then rapidly
decreased in the following intervals, in keeping with the plasma pharmacokinetic profiles (Figure 1).
Phase II derivatives of epicatechin accounted for 35.9% and 31.0% of total urinary metabolites after CC
and CC-PP intake, respectively, which suggests a limited bioavailability at the intestinal level.
Regarding microbial metabolites derived from epicatechin, phase II derivatives of
phenyl-γ-valerolactones and phenylvaleric acid were the most important group of metabolites
quantified in urine after the ingestion of both soluble cocoa products (64.1% and 69% of the total urinary
metabolites) and were largely excreted between 4–8 h post-intake. These compounds have been less
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described in the literature than phase II derivatives of epicatechin. Urpi-Sarda et al. [17] identified in
24 h urine mainly DHPVL and its phase II derivatives (glucuronides, sulfates, methoxy-glucuronides
and methoxy-sulfates), with some being also found in plasma after the intake of 46.4 mg of flavanols
in cocoa powder. Llorach et al. [29] revealed the presence of 4-hydroxy-5-(3′,4′-dihydroxyphenyl)
valeric acid in 24 h urine along with some phase II derivatives of DHPVL after the consumption
of a single dose of cocoa powder. Vitaglione et al. [9] also detected DHPVL in urine after the
intake of different products prepared with cocoa cream. Recently, Ottaviani et al. [8] completed the
characterization of phenyl-γ-valerolactones and phenylvaleric acid derivatives after consumption of 60
mg of [14C]epicatechin identifying sulfated and glucuronidated forms of DHPVL, HPVL and HDHPVA.
It is worth noting that excretion of HPVL-sulfate added up to 9.9 and 31.32 µmoles in 24 h after
CC and CC-PP intake, respectively, evidencing that sulfation was the preferential biotransformation
pathway followed by methylation and glucuronidation, in agreement with the profile described in
plasma. Consequently, HPVL-sulfate as the main metabolite in both plasma and urine, could be a very
sensitive biomarker of flavanol intake, considering that the excreted amount of this metabolite reached
41.1% and 38.5% of the total metabolites excreted after the consumption of CC and CC-PP, respectively.
Finally, derivatives of hydroxyphenylpropionic, hydroxyphenylacetic, hydroxybenzoic,
hydroxycinnamic, and hydroxyhippuric acids were also characterized. These compounds are not
exclusively formed during the biotransformation of flavanols, since most were present in basal urine
before soluble cocoa product intake (Tables 4 and 5) and, therefore, they were not taken into account to
determine flavanol recovery.
The total urinary excretion of metabolites derived from flavanols in CC and CC-PP presented a
recovery of 35.3% and 34.6% of the phenols ingested, respectively, pointing to a moderate bioavailability
of flavanols. It is worth noting that, although urinary recovery of metabolites, both from intestinal and
colonic absorption, showed a dose-dependent increase after CC and CC-PP intake, the total amount
of excreted metabolites was similar in both cases, around 35% of the ingested polyphenols, pointed
out the limited bioavailability of cocoa flavanols. There is a marginal difference between the data
reported in the literature regarding the recovery of flavanols. For instance, Baba et al. [27] showed an
epicatechin excretion of 29.8% and 25.3% after the ingestion of chocolate and cocoa, respectively, which
provided 220 mg of flavanols. Ito et al. [30] reported an excretion of 1.9% after the ingestion of 289 mg
of flavanols in a soluble cocoa administered with water. Mullen et al. [25] described excretions of 18%
and 10% after the ingestion of a beverage containing 13 mg of cocoa flavanols dissolved in water or
milk, respectively. Afterwards, Actis-Goretta et al. [16] reported excretion values of 21.7% following
the ingestion of 100 g of dark chocolate that provided 154 mg of flavanols. Recently, jejunal absorption
of (−)-epicatechin in humans assessed by an intestinal perfusion technique revealed an average of
~46% (−)-epicatechin absorption based on recovery in the perfusion fluid, with high inter-individual
variability among the eight volunteers participating in the study, ranging from 31% to 90% [31]. More
recently, Ottaviani et al. [8] determined that the mean total recovery of radioactivity in urine from
8 volunteers in a 0–48 h period after ingestion of [14C]EC was 82.5 ± 4.7% of intake, with individual
values ranging from 49.9% to 90.2%. In most volunteers, only a relatively small amount of radioactivity
was excreted after 48 h (8; 21). It is remarkable that in all these studies there are important differences
in the designs of the interventions, treatments applied to the samples before the analysis, quantification
methods and even in the form of administering the flavanols (dark chocolate, milk chocolate, cocoa
powder dissolved in water or milk), so that there are variables that can significantly affect the results,
making comparisons difficult. Of all the factors mentioned, the matrix effect of the food has been the
subject of numerous studies and, although they have generated controversial results, there are more
studies that suggest an interference of milk proteins in the absorption of flavanols, as described in
Mullen et al. [25], among others. High inter-individual differences in the production of metabolites
have been detected in this study, as in most previous studies here cited, since different factors such as
sex, age, dietary habits, and gut microbiota may significantly influence the absorption and metabolism
of phenolic compounds. Among the mentioned factors, the colonic microbiota is arguably the most
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important factor affecting the inter-individual variability, considering that metabolites formed at
colonic level constitute the predominant circulating metabolites. Nevertheless, all studies, including
the present work, suggest modest recovery of flavanols in urine considering only epicatechin-derived
phase II metabolites.
A limitation of this study was the reduced urinary collection time. Most of the microbial
metabolites show relevant amounts in the 12–24 h interval, not returning to basal levels, and therefore
it would have been interesting to extend the collection time to at least 48 h. Therefore, it is likely that
the amount of urinary metabolites has been underestimated and thus a higher bioavailability of cocoa
polyphenols cannot be ruled out. Another limitation was the lack of certain metabolite standards,
mainly phase II derivatives, forcing to express the results as equivalents of the corresponding precursor
compound. Therefore, the results here indicated did not accurately measure the concentrations of the
metabolites described in the biological samples. Nevertheless, the results are in line with other studies
on the bioavailability of cocoa flavanols [4,16,25].
In summary, polyphenols contained in two commercial, soluble cocoa products were partially
absorbed and extensively metabolized. Phase II derivatives of epicatechin were identified and their
pharmacokinetic profiles were compatible with epicatechin absorption at small intestine level. However,
the predominant group of metabolites identified corresponded to those formed by the microbiota,
hydroxyphenyl-γ-valerolatones and phenylvaleric acid, which were absorbed and metabolized into
phase II derivatives. Among these metabolites, 5-(hydroxyphenyl)-γ-valerolactone 3′-sulfate showed a
high amount in urine, which could be used as biomarker of intake of flavanol-rich food. In all, although
flavanol bioavailability, determined by urinary recovery, showed a dose-dependent absorption after
consuming both cocoa products, this was partial and limited to 35% of the ingested polyphenols,
irrespective of the initial dose.
In conclusion, the bioavailability of flavanols in soluble cocoa products is moderate, these
compounds are extensively metabolized, mainly by the microbiota, and remain in the body of cocoa
consumers for a long time, which favors the possible bioactivity of these compounds.
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identified determined by LC-ESI-QToF-MS.
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